Literature DB >> 34984578

LncRNA LOXL1-AS1 Facilitates the Oncogenic Character in Cervical Cancer by the miR-526b-5p /LYPLA1 Axis.

Yanhua Zhang1, Meng Zheng1, Lingyan Zhang1, Ping Yuan1, Jianbo Zhou1, Yongfang Wang1, Haihong Wang2.   

Abstract

Increasing reports demonstrate that long noncoding RNAs participate in the regulation of numerous malignancies, cervical cancer included. Although lncRNA LOXL1 antisense RNA 1 has been commonly accepted to be an oncogene in many cancers. Here, the role of LOXL1-AS1 in CC still need to be explored. In this study, LOXL1-AS1 was found elevated in CC tissues and cells. LOXL1-AS1 depletion restrained CC cell proliferation, migration, invasion, and angiogenesis in vivo. Furthermore, we found that LOXL1-AS1 upregulated Lysophospholipase 1 expression via sequestering miR-526b-5p. Rescue assays revealed that overexpression of LYPLA1 reversed the LOXL1-AS1 silencing-induced inhibitory effects on the malignant phenotypes of CC cells. To conclude, this study showed that LOXL1-AS1 facilitates cellular process in CC via functioning as a miR-526b-5p sponge.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cervical cancer; LOXL1-AS1; LYPLA1; miR-526b-5p

Mesh:

Substances:

Year:  2022        PMID: 34984578     DOI: 10.1007/s10528-021-10182-4

Source DB:  PubMed          Journal:  Biochem Genet        ISSN: 0006-2928            Impact factor:   2.220


  2 in total

1.  Inhibition of cell proliferation and migration in non‑small cell lung cancer cells through the suppression of LYPLA1.

Authors:  Anaz Mohammed; Caixin Zhang; Shuwen Zhang; Qin Shen; Jieying Li; Zhiyuan Tang; Hua Liu
Journal:  Oncol Rep       Date:  2018-11-09       Impact factor: 3.906

2.  LncRNA LOXL1-AS1 promotes invasion and proliferation of non-small-cell lung cancer through targeting miR-324-3p.

Authors:  Ning Xie; Xiuqu Fei; Shuliang Liu; Jie Liao; Youjie Li
Journal:  Am J Transl Res       Date:  2019-10-15       Impact factor: 4.060

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.